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Capsule endoscopy (CE) was found to be an effective tool in diagnosis of small bowel pathology.
This review will focus on its role in Crohn's disease. Its role in patients with suspected Crohn's
disease (CD) is described. CE has an established role for diagnosing CD when other tests are
negative, though it is not a first line investigative tool in these patients. Over diagnosis is of
concern. Its use in established CD remains an open question. It can provide exact mapping of
small bowel disease before surgery, and might have impact on the treatment of the disease. It
may have role in monitoring mucosal healing, which is becoming a target of therapy, and may
help establish the exact diagnosis in a limited group of patients with indeterminate colitis.
Retention of CEmight occur. It is of low rate in patients with suspected CD and higher in patients
with known CD but clinical obstruction is extremely rare. Economic considerations are a limit to
a wider application of the CE.
© 2007 European Crohn’s and Colitis Organisation. Published by Elsevier B.V. All rights reserved.KEYWORDS
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Capsule endoscopy (CE) is a minimally invasive means of
evaluating the small intestine. In this elegant technique, the
patient is given a small capsule to swallow. This is a disposable
26×11 mm video capsule (Given Imaging, Yokneam, Israel)
containing its own optical dome, light source, batteries,
transmitter and antenna. The pictures (2 per second) are
transferred via sensor arrays to a recorder and are downloaded
for reviewing. This minimally invasive modality that took up to
the challenge of literally viewing the entire small bowel was
introduced by Gabriel Idan in 2000.1 The capsule has been with
us for seven years and over 700 publications regarding its use in
various clinical settings have been published. Recently the FDA
has approved the second-generation capsule for use. This
capsule has an improved angle of view, better illumination, and
automatic light control. The new Rapid 5 software contains an
atlas and a scoring system for IBD (the Lewis score) incorporated
in it (Fig. 1). There are some additional small bowel capsule
systems that are approved for use in different parts of theworld,
none of which is yet, to our knowledge, except the Olympus
EndoCapsule (Olympus Japan) is FDA approved. These include
the Chinese OMOM pill (Jinshan science & technology, Chongq-
ing, China) and the Korean MicroCam (Intromedic, Seol Korea).
This review will focus on the Given capsule endoscope and
its role in Crohn's disease.
Crohn's disease is an inflammatory disease of the gastro-
intestinal tract. Any part of the gastrointestinal tract from the
mouth to the anus could be involved. Standard endoscopy
procedures enable vision of only a small part of the small
intestine. With these procedures, only the first, second and
the beginning of the third part of the duodenum (gastro-
scopy), and the terminal ileum (colonoscopy) are seen. When
enteroscopy is preformed, some of the distal duodenum and
proximal jejunum can be scoped, but the vast part of the
small intestine cannot be reached, unless the newly intro-Figure 1 PillCam SB2.duced double balloon system is used. The remainder of the
small intestine could be imaged by roentgen (CT MRI or small
bowel follow through). Up to the introduction of CE, we were
somewhat blind to a major part of the small intestine. Since
its introduction and usage many questions have arisen. Does
the capsule enable viewing of the whole small intestine?Will it
change patient management in Crohn's disease? If so, when
should it be used in patients suffering from Crohn's disease, or
suspected to have Crohn's disease? Should it be used only when
the classic techniques fail? Are there special considerations to
be taken when evaluating a patient with known Crohn's
disease with CE compared to other indications?
When evaluating the sensitivity and specificity of a new
technique, it should be compared to a gold standard test, but
no gold standard test for visualization of the small intestine
exists. Studies evaluating the sensitivity and specificity of the
capsule are somewhat problematic in this sense. Another pitfall
is an incomplete examination,which has been found to occur in
about 20% (15–35%) of cases.2–5 While some clinical settings
such as obscure gastrointestinal bleeding are readily validated
and widely accepted,6 others are still under investigations.
1.1. What about Crohn's disease?
Erosions and ulcerations can be detected with a high degree
of accuracy with CE.7 Thus, in a patient with Crohn's disease,
the capsule allows to diagnose the extent of disease. The
meaning of the findings in a patient with suspected Crohn's
disease is somewhat more complicated. Does the patient
with erosions and/or ulcerations suffer from Crohn's disease,
are these findings secondary to non-steroidal anti inflamma-
tory drug usage, or are they just part of the “normal”
spectrum with no clinical significance, as has been described
in some studies in up to 14% of normal subjects.8 Part of the
answer has been given by Maiden et al. who included healthy
volunteers in their study. They demonstrated that if 4 weeks
of abstinence from NSAID were kept, no erosions were found
in the small bowel.9
We will address the following clinical situations in which
CE might be useful and relevant:
1. Diagnosis of Crohn's disease.
2. Defining extant of Crohn's disease.
3. Differentiating between Crohn's disease and Ulcerative
Colitis (UC) in a patient with indeterminate colitis (IC).
4. Monitoring postoperative recurrence.
5. Assessment of mucosal healing.
6. Risks and how can they be minimized?
7. Economic considerations.
2. Diagnosis of Crohn's diseaseAbdominal pain, diarrhea, weight loss, anemia, and labora-
tory signs of inflammation may indicate Crohn's disease.
Table 1 Diagnostic yield of CE in patients with suspected CD3,5,10–17
1st author No
patients
Indication Diagnostic yield
for Crohn's (%)
Comparative studies
May 50 Abdominal pain+1≥objective sign 26 Colonoscopy and gastrocopy
Shim 110 Abdominal pain 3 Various
De Bona 12 Abdominal pain 8 Various
26 Abdominal pain+markers of
inflammation
46
Chong 21 Suspected CD 10 Push enteroscopy, enteroclysis, and CE — same
yield
Eliakim 35 Suspected CD 77 CTE or SBFT 26%
Fireman 17 Suspected CD 71 Colonoscopy, gastroscopy and SBFT — 0%
Liangpunsakul 40 Abdominal pain+/−anemia 8 Colonoscopy, gastroscopy and SBFT — 0%
Herrerías 21 Suspected CD clinical+ laboratory 43 Colonoscopy — 5%, gastroscopy and SBFT — 0%
Argüelles-
Arias
12 Suspected CD 58 Colonoscopy, gastroscopy and SBFT — 0%
Ge 20 Suspected CD 65 Colonoscopy, gastroscopy and SBFT — 0%
CTE = CT enterography.
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taking, physical examination and basic laboratory tests,
where upon a decision is made as to whether the patient
should undergo further evaluation. This evaluation consists
of endoscopic examinations, colonoscopy with ileoscopy,
and radiographic tests: CTor MRI enteroscopy, and/or small
bowel follow through (SBFT). When these tests are negative
a decision should be made whether the signs and/or
symptoms justify further evaluation. It is this group of
patients that most CE studies are focused on: patients with
suspected Crohn's and negative radiologic/endoscopic
workup. Of note is the fact that ileoscopy was not preformed
in about 50% of the patients studied in this setting. To date,
10 studies have assessed the usefulness of the capsule in
diagnosing Crohn's disease10–17 (Table 1). The studies are
not uniformly designed, so it is not surprising that the
outcomes are different. Earlier studies included highly
selected patients with a high degree of suspicion. In this
group of patients, the yield of Crohn's diagnosis was
~70%.12,13 Recent studies have included a less selected
group of patients. In these studies, the diagnostic yield was
much lower ~20% (8–60%). The yield is lowest when the only
subjective finding is abdominal pain, as opposed to more
objective findings (weight loss or inflammatory laboratory
findings) are present.5,12 Whether the yield is 70% or 20%,
there is a general agreement that, if there is a suspicion of
Crohn's disease and the workup is negative but the physician
perceives that further investigation is warranted, CE should
be considered as the next step. When CE is preformed, there
is a tradeoff — higher sensitivity but lower specificity.
Therefore, we recommend that CE be done after at least
1 month off NSAIDs and the results be described judicially,
taking into consideration clinical presentation as well as
additional tests so that over diagnosis is avoided.7,18 Several
groups are trying to develop a CE scoring system so that all
physicians interpreting CE results will speak the same
“language”. Recently, Gralnek et al. defined three major
scoring parameters — villous edema, ulceration, and
stenosis. Each parameter was defined by a numericalscore. The results are thereupon summed, according to
the sum, a conclusion of no or clinically insignificant
change, mild change, and moderate or severe change is
reached.19
Algorithm formanagement of patientwith suspectedCrohn's
disease was published by the consensus group at the interna-
tional conference for capsule endoscopy (ICCE)20 (Fig. 2).3. Defining the extent of Crohn's diseaseCrohn's disease can involve any part of the gastrointestinal
tract. Up to the invention of CE, there was no good way to
directly visualize the small intestine. While the capsulemight
have added value in providing a better view of the small
intestine, one needs to ask himself whether this is important,
i.e., does it have an impact on patient management and
when. The main medical treatment for Crohn's consists of 5-
ASA, steroids, antibiotics, immunosuppressants, and anti TNF
medications. The decision regarding treatment relies on
thorough clinical evaluation. In most patients, the exact
‘mapping’ of involvement will not change management.
Voderholzer et al. described a change in management of 10
out of 56 patients due to the findings of CE.21 In another study
by Mow et al., 17 of 20 patients with definite findings on CE
improvedwith increased IBD-directedmedical therapy, as did
7 of 10 patients with suspicious study results.22 The major
indication for the use of CE in this group of already diagnosed
Crohn's patients is limited to a few situations: One might be
when there are abdominal complaints in the face of normal
laboratory results (to seeweather there is inflammation or its
IBS). Another setting might be to view the small bowel when
there is unexplained anemia/blood loss in patients with
Crohn's colitis. A 3rd setting might be to monitor small bowel
mucosal healing after various treatments, or as a prognostic
tool, perhaps guiding treatment (mainly in research settings
at this point). A 4th setting might be when surgical treatment
is considered, when it might be important to “map” the exact
Figure 2 Algorithm of suspected Crohn's disease.
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can be perceived as a “stress test” for strictures, as other
non-invasive tests, such as SBFTor CT, are less reliable for the
diagnosis of strictures. If the patient has obstructive
symptoms suggestive of strictures and other tests are
negative, CE can indicate if there is a stricture and give a
presumptive localization.
The only complication of CE described so far is retention,
which might occur when a stricture exists (see the section
regarding complications). In these specific scenarios, if the
capsule is not expelled, it should not be perceived as acomplication, but rather as a guide to the surgeon to define
the location of a significant stricture so that it can be treated
adequately.23,24 Another subgroup where CE might be helpful,
indeterminate colitis will be discussed separately.4. Indeterminate colitis (IC)
There is no generally accepted definition for IC.25 All current
applications of the termrely onexclusionary criteria and there is
no confirmatory diagnostic test. Nevertheless, the diagnosis of
111Capsule endoscopy in Crohn's disease — Indications and reservations 2008IC appears to be found in about 10% of patients with IBD,
suggesting that this group represents a uniquephenotype. In this
group of patients, there's an unclear inflammatory involvement
in the colon while other tests are negative. CE may show small
bowel involvement, thereby defining the disease as Crohn's as
opposed to UC or IC. Mow et al. were the first to investigate this
condition. They investigated 22 patients — 17 fitting into the
above description and five with ileo-anal anastomosis (IAA).
Relevant findings on CE suggestive or diagnostic of Crohn's
disease, leading to a change inmanagement, were found in half
the patients.22 Recently, Maunoury et al. 26 reported on CE
findings in 30patientswith IC. Elevenwereeventually diagnosed
with Crohn's disease, five with the help of CE, and six after
repeat endoscopy with ileoscopy. In another study sixteen
patients considered to have UC underwent colectomy. After
surgery, they suffered from chronic pouchitis. Fifteen of them
were examined by CE. All 15 were found to have lesions
consistent with Crohn's disease.27
5. Monitoring postoperative recurrence
Four studies assessed the utility of the CE in assessing
postoperative recurrence of Crohn's disease.28–31 They were
performed 6–12 months after surgery. The studies in which CE
was preformed one year after surgery showed postoperative
recurrence in the small bowel in nearly 100% of patients. In the
studyperformed6months after surgery, involvementwas seen in
a smaller portion of patients. CE results were inferior to
ileoscopy in the neo-terminal ileum in most studies, but were
superior and gave new information regarding the upper small
bowel, as expected. On the whole, if endoscopic recurrence
reaches 100% one year postsurgery, it could be argued that no
endoscopic evaluation of any sort is needed at this stage, and
management should be given accordingly or if there are clinical
indications. Unless re-operation is considered ormucosal healing
is sought as a means of treatment follow-up (see section on
mucosal healing), the capsule does not seem to be indicated in
this group of patients.
6. Assessment of mucosal healing
There are many clinical and laboratory markers of inflamma-
tion. None is specific and their sensitivity is subject to great
variability. On the whole, these tools are far from ideal.
Immunomodulator and Infliximab have been found to induce
colonic mucosal healing at different rates; this seems to be
the most reliable tool for assessing Crohn's disease activity
and has recently been associated with decreased hospita-
lization and operation rate.32 There is no study that as-
sessed the utility of CE to detect mucosal healing, but its
sensitivity formucosal pathology has been established and it
is reasonable to assume that it can be applied in this setting.
Therefore, if and when mucosal healing becomes standard
in assessing therapeutic interventions and disease activity,
there will be a probable role for CE in this setting, but
remains to be proven.
7. What are the risks and how can they be
minimized?
The only complication of CE is non-natural excretion (NNE).
Most impactions do not cause acute intestinal obstruction,although this has been described on rare occasions.33,34
Impaction occurs when there is an unforeseen stricture. The
rates of NNE of CE are not accurate as patients were
excluded from studies if there was any suspicion of a
stricture. This could have been on clinical grounds
(obstructive symptoms), or imaging modalities findings.
Even with these precautions, some capsules were retained,
necessitating endoscopy, sometimes with the help of a
double balloon35,36 or surgical retrieval. In many cases,
surgery was more than just retrieval of the capsule, but
actually therapeutic with resection of the stricture itself.
The propensity for retention is different with varying
indications. In a large retrospective study consisting of
733 patients referred for various reasons (mainly obscure GI
bleeding), retention occurred in 14 patients (1.9%).2 Eleven
of these patients had normal radiologic small bowel
examinations, demonstrating that this is not a reliable
means of detecting strictures. The highest percentage of
NNE was observed in patients with established Crohn's
disease. In a recently published report, retention in
patients with known Crohn's disease occurred in five of 38
(13%) patients; of these, three strictures were unknown
beforehand. Retention occurred in one of 64 patients with
suspected Crohn's disease.37 The overall retention rate for
patients with suspected Crohn's is 1.4%. When retention is
suspected — a plain abdominal film should be obtained after
2 weeks. If retention is confirmed endoscopic or surgical
removal should be planned. Retrieval of capsule is usually
preformed on an elective basis, unless the patient is
symptomatic.38
As radiologic examinations are unreliable for the detec-
tion of strictures, and seeking for a better solution in
patients with obstructive symptoms or in high risk, brought
about the development of the “patency capsule” (PC). The
PC consists of a biodegradable body surrounding a small
radiofrequency identification tag. If the PC is excreted
intact, it is presumed that no significant stricture is
present. In the presence of a stricture, the PC disintegrates
into small fragments and is excreted along with the
radiofrequency tag. A scanner is used to detect the
radiofrequency tag externally. There are five studies
assessing the yield and safety of the PC.39–43 Two main
points were investigated. The first is the PC's ability to
determine which patients could have the real CE per-
formed, and the second is the safety of the PC itself. A total
of 134 patients were studied in these four studies. Not all
the patients who had “clearance” to perform the real CE
procedure actually did so, but the 62 patients who under-
went the procedure had no complications. Four of 134
patients (2.9%) had to undergo surgery due to impaction of
the PC itself. Although it could be assumed that most of
these patients would have needed surgery irrespective of
the PC impaction, it is still a disturbing point to be taken
into account and explained to the patient. In order to solve
the problem outlined above, a new generation of PC has
been developed. This new generation PC, the AGILE
capsule, disintegrates to smaller particles, therefore is
designed to pass even when a stricture exists. Herrerías et
al. preformed a study utilizing the Agile PC in 106 patients
with evidence of intestinal stricture. In 47 patients the
capsule disintegrated, therefore stricture was established,
none of which suffered from clinical obstruction.44
112 I. Chermesh, R. Eliakim8. Economic considerations
CE is perceived an expensive test. Therefore, it is somewhat
surprising to learn that this test might actually save money.
Eisen performeda thorough economic evaluation of the capsule
for various indications.45 On the whole, patients underwent
6.77 negative diagnostic procedures before being referred to
CE. These tests are costly, some invasive or requiring X-ray
exposure. CE is non-invasive, allows visualization of the entire
small bowel in most patients, and is accurate. It might enable
earlier diagnosis and treatment which can save money, with
more days of well-being and less loss of working days.
Concerning Crohn's disease specifically, it was calculated that
the capsule is economic if the diagnostic yield is 64% or higher.
9. Conclusion
At this stage, CE should be done in patients with suspected
Crohn's disease or indeterminate colitis, a month after NSAID
stoppage, when other tests are negative. It may have an even
bigger role, in earlier stages of the investigation, when the
price is lowered andphysicians accumulate greater experience.
The role of CE in patients with established Crohn's disease is yet
to be defined. It will most probably serve as an indicator of
mucosal healing after treatment, or of significant strictures
before surgery.
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